Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | HTR6 | P50406 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | PGR | P06401 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29118855 | 1.00 | LMNA (0.73) | LMNAGAAMAPK1HTR6ALDH1A1 | |
| SCHEMBL12167748 | 0.95 | PGR (0.76) | LMNAGAAMAPK1HTR6ALDH1A1 | |
| SCHEMBL790294 | 0.91 | GAA (0.86) | LMNAGAAMAPK1ALDH1A1PGR | |
| SCHEMBL18386666 | 0.86 | CA1 (0.69) | HTR6ALDH1A1PGRHTTCA1 | |
| SCHEMBL32679643 | 0.86 | GAA (0.78) | LMNAGAAMAPK1ALDH1A1PGR | |
| SCHEMBL540915 | 0.86 | CA1 (0.85) | HTR6ALDH1A1HTTCA1CA2 | |
| SCHEMBL11793140 | 0.86 | CA1 (0.85) | HTR6ALDH1A1HTTCA1CA2 | |
| SCHEMBL7823465 | 0.85 | HTR6 (0.88) | LMNAHTR6HTTCA1CA2 | |
| SCHEMBL806437 | 0.85 | GAA (0.76) | LMNAGAAMAPK1ALDH1A1PGR | |
| SCHEMBL29031235 | 0.85 | PGR (0.85) | LMNAGAAMAPK1ALDH1A1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084744-A | Aloe-emodin derivative and preparation method and application thereof | 广西民族大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-115955968-A | Carbohydrazone acyldinitrile compounds comprising at least two aryl or heteroaryl groups connected by a novel linker and uses thereof | 韩国科学技术研究院 | 2023-04-11 | — | — | CN | disclosed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011022393-A2 | PHOSPHATIDYLCHOLINE TRANSFER PROTEIN INHIBITORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| CN-101074242-A | Cells accumulation for sphosphonate analogs of HIV protease inhibitor compound and the same compound | GILEAD SCIENCES INC (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-1313472-C | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2007-05-02 | — | — | CN | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| CN-1110489-C | Benzisoelenazolone sulfamide derivative, its preparing process and its application in preparing medicines | INST OF PHARMACOLOGY CHINESE A (CN) | 2003-06-04 | — | — | CN | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| CN-1253135-A | Benzisoelenazolone sulfamide derivative, its preparing process and its application in preparing medicines | INST OF PHARMACOLOGY CHINESE A (CN) | 2000-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | LMNA 3472/4885GAA 3857/4885MAPK1 2121/4885 |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | LMNA 1833/4885GAA 639/4885MAPK1 3018/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | LMNA 4090/4885GAA 4207/4885MAPK1 2357/4885 |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | LMNA 2096/4885GAA 2338/4885MAPK1 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.